Details for New Drug Application (NDA): 217307
✉ Email this page to a colleague
NDA 217307 describes ZOLYMBUS, which is a drug marketed by Thea Pharma and is included in one NDA. There is one patent protecting this drug. Additional details are available on the ZOLYMBUS profile page.
The generic ingredient in ZOLYMBUS is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
The generic ingredient in ZOLYMBUS is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for 217307
| Tradename: | ZOLYMBUS |
| Applicant: | Thea Pharma |
| Ingredient: | bimatoprost |
| Patents: | 1 |
Medical Subject Heading (MeSH) Categories for 217307
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;OPHTHALMIC | Strength | 0.01% | ||||
| Approval Date: | Sep 9, 2025 | TE: | RLD: | Yes | |||||
| Patent: | 10,314,780 | Patent Expiration: | Jun 8, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION | ||||||||
Complete Access Available with Subscription
